• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: dexamethasone intravitreal implant
Trade Name: Ozurdex
Date Designated: 09/11/1998
Orphan Designation: Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis
Orphan Designation Status: Designated/Approved
Allergan
2525 Dupont Drive
Irvine, California 92623
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: dexamethasone intravitreal implant
Trade Name: Ozurdex
Marketing Approval Date: 09/24/2010
Approved Labeled Indication: For treatment of non-infectious uveitis affecting the posterior segment of the eye
Exclusivity End Date: 09/24/2017 
Exclusivity Protected Indication* :  

*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.
-
-